Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart)
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DapaHeart
- 06 Oct 2023 Results investigating changes in HDL modulation of nitric oxide production with dapagliflozin and whether there is an association with myocardial flow reserve, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 19 Dec 2022 Status changed from recruiting to discontinued.
- 29 Aug 2022 Primary endpoint (Effect of dapagliflozin on myocardial insulin sensitivity) has not been met, according to Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.